Ayoade Joy Ademuyewo founded Lokum last year to create a solution to better connecting medical specialists with health care facilities nationwide. Photo courtesy of Lokum

Ayoade Joy Ademuyewo says that anesthesiology is “the coolest thing in the world.” That’s why she became a certified registered nurse anesthetist.

And that career, which she says is “the perfect blend of science and art,” led to the creation of her startup, Lokum.

Lokum App is a matchmaking engine that aims to connect Ademuyewo’s peers with jobs. She explains that before her innovation, staffing for nurse anesthetists traditionally owed to job boards 30 years older than she was or to recruitment agencies that left them at a disadvantage.

“I didn't want to use that job board because it was sort of difficult to use and I didn't want to use it and a lot of other people felt the same way,” she recalls.

When a desperate friend asked for her help navigating the terrain of finding CRNA work as an independent contractor, Ademuyewo says the wheels began turning in her mind.

“I just thought, 'Why can't I open up my phone and see all of the available jobs to me, based on my preferences and my skills? And I can easily select from them to go to my next job.' And that's sort of where the questions started. And I just kept asking those questions. And I think about two or three years into asking the questions I was like, 'Oh my gosh, I think I'm starting a company,'” Ademuyewo says.

In the hours that she wasn’t in surgery, the CRNA began doing market research.

“As I was studying the market, and mapping it out, these really complex mind maps started to happen. And it was almost a natural conclusion that the more you understand the problem, the more the solution starts to appear to you,” she explains.

And she saw that the obvious solution was also potentially a big opportunity for her to create something entirely new — neither a job board nor an agency, but something entirely new. Ademuyewo calls Lokum a “matchmaking engine.” It takes the preferences, specialties and skills of CRNAs like her and matches them to jobs that make sense for them. To date, the pilot has connected users with around 200 hospitals and clinics in 20 states.

Fortunately, because there are so few CRNAs in practice, they are a unified bunch.

“It’s a really well-networked profession,” says Ademuyewo. “ I'm lucky to be in a profession where what we do is really special and really specialized.”

Because she was already part of the tight knit community, the founder had no trouble finding pilot customers. She worked with Houston-based Octaria Software to engineer the technical side of the app, as well as another local cybersecurity firm to work on infrastructure.

Lots of big news has come for Ademuyewo in the first half of 2024. She participated in this year’s cohort of the Google for Startups Accelerator Program-North America, which she says helped to gain traction in her fundraising amid a bear market.

The result? Early this month, Lokum announced a raise of $700,000 in pre-seed funding, which will be allocated to improving and enhancing the existing technology. Those funds came from Houston investors including Aileen Allen, of the Houston Angel Network, Mercury, and The Artemis Fund; and Matt Miller, former Liongard product executive, as well as from Houston-based VC firm South Loop Ventures. More came from the non-local JP Morgan and Techstars.

Today, Ademuyewo is devoted full-time to Lokum, though she still practices her favorite combination of science and art on weekends in order to maintain her licensure.

“I will always be clinical, that will never change,” she says. “Part of that is just staying close to the problem and the people who are experiencing it, I think that is exactly the right thing for me to be doing.”

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston cleantech, space startups named to World Economic Forum cohort

top honor

Two Houston-based startups have been selected to join the World Economic Forum's Technology Pioneers community.

The two-year program aims to help mission-driven, early-stage start-ups scale their innovations through multi-stakeholder initiatives, co-creating partnerships and other gatherings for community members. One-hundred startups are selected each year from around the globe, this year hailing from 23 countries and working in AI, energy, space, biotech markets and more.

Cleantech startup Vaulted Deep was one of 11 energy and climate companies to be named to the cohort. Julia Reichelstein and Omar Abou-Sayed founded the company in 2023. Its technology injects excess organic waste underground to remove carbon dioxide from the atmosphere.

Last year, Vaulted Deep inked a 12-year deal with Microsoft to remove up to 4.9 million metric tons of carbon dioxide from the environment.

The startup has earned several accolades in recent years, including a No. 3 spot on Fast Company’s list of the World’s Most Innovative Companies of 2026. It was also recently named to market intelligence and advisory firm Cleantech Group's annual Global Cleantech 100 list for a second year in a row.

"Waste management is one of the world's great invisible infrastructure systems ... The need for new infrastructure is growing as disposal challenges become more complex and regulations evolve. Vaulted is building the first new disposal pathway for organic waste in decades by putting it deep underground, permanently," the company shared in a LinkedIn post. "This year, we're joining the World Economic Forum's 2026 Tech Pioneers alongside innovators working on the many interconnected challenges shaping our future."

Houston-based Venus Aerospace was also selected to join the cohort, along with six other spacetech companies. The company was founded in 2020 by Sassie and Andrew Duggleby.

The startup specializes in next-generation rocket engine propulsion as a cleaner alternative to traditional combustion engines. The company's rotating detonation rocket engine (RDRE) burns fuel more efficiently and completed a successful high-thrust test flight last year. Venus says it’s the only company in the world that makes a flight-proven, high-thrust RDRE with a “clear path to scaled production.”

"Frontier technologies matter most when they expand what people, industries, and nations can do," Sassie Duggleby, co-founder and CEO of Venus, said in a news release. "For Venus, RDRE does not just represent a more efficient engine. It is a foundation for faster movement, more capable space systems, and new forms of connectivity across the planet. Being named a Technology Pioneer validates the potential of this technology to help shape a future where distance is less limiting."

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston Methodist receives record $110M gift, names future tower

historic gift

Houston Methodist has received the largest gift in the health system's history to establish new funds for neurological, neuroscience, and women’s health research and treatment.

The $110 million gift comes from Houston-based The Brockman Medical Research Foundation, which supports education and research in the science, medicine and healthcare fields. In response, Houston Methodist announced that it will name its forthcoming 26-story hospital facility the Brockman Centennial Tower.

The tower’s entrance will be named the Anna Margaret Bellows Centennial Hall to honor Anna Margaret Bellows, a young camper who died during the Camp Mystic flooding last summer.

“This extraordinary gift accelerates discovery and transforms how care is delivered,” Dr. Marc Boom, president and CEO of Houston Methodist, said in a news release. “We are grateful to The Brockman Medical Research Foundation for its incredible generosity and vision that will help change the lives of generations of patients. Naming Centennial Tower in recognition of this gift reflects the scale of this commitment and its impact on the future of neuroscience, neurological care and women’s health.”

The gift will be divided into two parts:

  • $100 million will go toward creating an innovation fund within the Houston Methodist Academic Institute and the Houston Methodist Neurological Institute
  • $10 million will be devoted to Houston Methodist's Department of Obstetrics and Gynecology

“This tremendous gift will accelerate translational research that broadens our understanding of neurological and other diseases,” Dr. Jenny Chang, president and CEO of the Houston Methodist Academic Institute, added in the release. “It will allow us to leverage state-of-the-art platforms to detect, diagnose and deliver therapeutics, keeping patient care at the center of our mission.”

The Brockman Centennial Tower is expected to open next year in the Texas Medical Center. Spanning more than 1 million square feet, it will house 400 patient beds, an expanded emergency department, new operating rooms and a rooftop garden. It will be connected to Houston Methodist's flagship Paula and Joseph C. “Rusty” Walter III Tower, which opened in 2018. The Centennial Tower was estimated to cost $1.4 billion when announced in 2022.

In addition to the news of the Brockman gift, Houston Methodist also announced this month that it has launched the Houston Methodist Center for Cell and Gene Therapy and tapped an internationally recognized scientist as its leader.

The new center is focused on discovering and developing innovative and cost-effective therapies for a variety of congenital and acquired diseases, including cancer, HIV and cardiovascular disease.

Dr. Malcolm Brenner has been named as the center's inaugural leader and will assume the role starting in October. He will work alongside scientists and support staff from Baylor College of Medicine and Texas Children's Hospital.

Brenner is a professor of pediatrics, medicine, molecular and human genetics and translational biology at Baylor College of Medicine. He is known for making early advances in using bone marrow transplantation as a form of cell therapy and in engineered immune-cell treatments for cancer and infections, according to a release from Houston Methodist.

“Malcolm Brenner is a pioneer in the field of cell and gene therapy and is uniquely qualified to lead Houston Methodist’s research efforts in this field,” Chang added. “His vision and leadership will play a pivotal role in advancing our work in this space.”